Skip to main content
  • Phytochemical in a Himalayan plant inhibits the COVID-19 virus

    Researchers from the Indian Institute of Technology, Mandi, and The International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, have identified Phytochemicals in the petals of a Himalayan plant that could potentially be used to treat COVID-19 infections.

    The findings of the research team have been recently published in the journal Biomolecular Structure and Dynamics.

    admin Fri, 01/21/2022 - 15:39
  • Oral penicillin, not injectable, advised for people with high-risk rheumatic heart disease

    A growing body of evidence indicates that some people thought to have an allergic response to injectable penicillin, the standard treatment for rheumatic heart disease, may instead be experiencing a cardiac reaction to the medicine, according to a new American Heart Association presidential advisory published today in Journal of the American Heart Association.

    admin Wed, 01/19/2022 - 16:04
  • Health Canada authorizes PAXLOVIDTM for patients with mild to moderate COVID-19 at high risk of developing serious disease

    Health Canada has authorized the combination of two antiviral drugs, nirmatrelvir and ritonavir (brand name PAXLOVIDTM), to treat adults with mild to moderate COVID-19 who are at high risk of progressing to serious disease, including hospitalization or death. The active ingredient nirmatrelvir in PAXLOVIDTM works by stopping the virus from replicating.

    admin Wed, 01/19/2022 - 15:56
  • Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant

    Pfizer Inc shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron. Taken together, these in vitro studies suggest that PAXLOVID has the potential to maintain plasma concentrations many-fold times higher than the amount required to prevent Omicron from replicating in cells.

    admin Wed, 01/19/2022 - 15:51
  • BiologyWorks k(now) COVID-19 Clinical Trial matches 99.1 percent accuracy to RT-PCR Tests

    The independent clinical trial, conducted by Locus Medicus in Athens, Greece, prospectively tested 330 patients with symptomatic and asymptomatic cases of COVID-19. For the study, staff at the clinical laboratory collected two bilateral anterior nasal swabs from each patient. Immediately after collection, one swab was tested in the lab’s standard of care CE-Mark RT-PCR test and the other swab was tested by BiologyWorks k(now). Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests.

    admin Wed, 01/19/2022 - 14:56
  • Nuclei-free Cells Prove Utility in Delivering Therapeutics to Diseased Tissues

    Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health report successfully removing the nucleus out of a type of ubiquitous cell, known as enucleation, then using the genetically engineered cell as a unique cargo-carrier to deliver therapeutics precisely to diseased tissues.

    admin Tue, 01/18/2022 - 16:56
  • Nanotherapy offers new hope for the treatment of Type 1 diabetes

    Individuals living with Type 1 diabetes must carefully follow prescribed insulin regimens every day, receiving injections of the hormone via syringe, insulin pump or some other device. And without viable long-term treatments, this course of treatment is a lifelong sentence.

    admin Tue, 01/18/2022 - 16:53
  • New Method to Increase Effectiveness of Nanomedicines

    Researchers at Penn Medicine have discovered a new, more effective method of preventing the body’s own proteins from treating nanomedicines like foreign invaders, by covering the nanoparticles with a coating to suppress the immune response that dampens the therapy’s effectiveness.

  • Macrophages are fighting against plaque formation in the artery, suggests study

    A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behaviour within the vessel wall.

  • Molnupiravir has serious safety concern, says ICMR

    Antiviral medicine molnupiravir which recently got approval from the CDSCO in India and is being manufactured by many pharma companies, has serious safety concerns, and thus has not been included in the national COVID-19 clinical protocol recommended by the health ministry, the Indian Council of Medical Research (ICMR) director general Balram Bhargava said.

    Bhargava said the COVID-19 task force has debated twice whether to include the Molnupiravir in the COVID-19 treatment protocol but decided against it because of concerns.

Subscribe to Research News

Search this website